During 2012, the company said it received $96 million in up-front payments from Weston, Mass.-based Biogen Idec Inc

Earlier this year, for instance, Biogen Idec Inc.'s dexpramipexole failed to improve function or survival in a Phase III ALS study. (See BioWorld Today, Jan. 4, 2013.) Genervon could have better luck, since its ALS candidate, GM604, "controls and modulates more than 30 known and significant ALS genes with positive effects, through at least eight pathways – potentially more – concurrently, systemically and dynamically," Ko said

Kozul said the deal would represent a hedge for Royalty Pharma against any issues that might arise with BG-12, Biogen Idec's oral MS drug, which has a March 28 PDUFA date...Strip out the $3.25 billion cash Elan will receive for Tysabri, once its asset disposal deal with Biogen Idec, of Weston, Mass., closes, and Royalty Pharma's offer represents a discount of almost 17 percent on Elan's remaining royalty stream for the product, Parkes said

Mundipharma International Corp., of Cambridge, UK, said results from the StiL NHL-1 study published in The Lancet showed that a first-line treatment regimen of bendamustine plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG) doubled progression-free survival compared with CHOP plus rituximab in newly diagnosed patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma (69.5 months vs. 31.2 months; p < 0.0001

Kozul said the deal would represent a hedge for Royalty Pharma against any issues that might arise with BG-12, Biogen Idec's oral MS drug, which has a March 28 PDUFA date...Strip out the $3.25 billion cash Elan will receive for Tysabri, once its asset disposal deal with Biogen Idec, of Weston, Mass., closes, and Royalty Pharma's offer represents a discount of almost 17 percent on Elan's remaining royalty stream for the product, Parkes said

Kozul noted the deal would represent a hedge for Royalty Pharma against any issues that might arise with BG-12, Biogen Idec's oral MS drug, which has a March 28 PDUFA date...Strip out the $3.25 billion cash Elan will receive for Tysabri, once its asset disposal deal with Biogen Idec, of Cambridge, Mass., closes, and Royalty Pharma's offer represents a discount of almost 17 percent on Elan's remaining royalty stream for the product, Parkes said

Viropro Inc., of Washington, and Oncobiologics Inc., of Cranbury, N.J., signed a biosimilar collaboration agreement giving Viropro the rights to manufacture six generic versions of Humira (adalimumab, Abbott), Rituxan (rituximab, Biogen Idec Inc./Genentech Inc.), Avastin (bevacizumab, Genentech Inc.), Herceptin (trastuzumab, Genentech Inc.), Erbitux (cetuximab, Bristol-Myers Squibb Co./Eli Lilly and Co./Merck KgaA) and one other non-disclosed biotherapeutic product

Company Company Deal Value Biogen Idec Inc

Biogen Idec Inc. (Weston, Mass.) Isis Pharmaceuticals Inc. (Carlsbad, Calif.) $200 Partnership to discover and develop antisense drugs for several undisclosed targets in the area of neurological and neuromuscular disorders Biogen Idec will pay Isis $30M up front to discover a lead candidate for each of three targets, and Isis will be eligible for milestone payments...Biogen Idec also has an option to license a drug from each of those three programs through completion of Phase II trials

SAR3419 showed Phase I activity across an array of CD19 non-Hodgkin's lymphoma (NHL) histological subtypes, including disease that was refractory to rituximab (Rituxan, Biogen Idec Inc. and Roche AG) as well as rituximab-responsive NHL, and was generally well tolerated

Elan Corp., of Dublin, Ireland, said after the closing of the restructuring of the Tysabri collaboration with Biogen Idec Inc., of Weston, Mass., it plans to execute a number of strategic Initiatives: A portion of the $3.25 billion received from Biogen will be invested into a variety of business assets, which will diversify them from a product, science/clinical, therapeutic and geographic point of view

Mundipharma International Corp., of Cambridge, UK, said results from the StiL NHL-1 study published in The Lancet showed that a first-line treatment regimen of bendamustine plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG) doubled progression-free survival compared with CHOP plus rituximab in newly diagnosed patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma (69.5 months vs. 31.2 months; p < 0.0001

Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) Peginterferon beta-1a A pegylated form of Avonex Relapsing-remitting multiple sclerosis Produced a significant reduction in annualized relapse rate and also met its secondary endpoints in a Phase III trial 1/25/13 CANCER Aeterna Zentaris Inc. (Quebec City) AEZS-108 A luteinizing hormone-release hormone-targeted cytotoxic conjugate Endometrial cancer Agreed with the FDA on an SPA for a Phase

Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) and Elan Corp...inhibits enzyme glutathione S-transferase P1-1 Myelodysplastic syndrome Was granted orphan designation by the FDA 1/15/13 CARDIOVASCULAR Biogen Idec Inc. (Weston, Mass.) rFIXFc Recombinant factor IX FC fusion protein Hemophilia B Submitted a BLA 1/7/13 Isis Pharmaceuticals Inc. (Carlsbad, Calif.) and Genzyme (unit of Sanofi SA; Paris) Kynamro Systemic antisense drug

Other cancer drugs have been approved with warnings about TLS, including Rituxan (rituximab, Biogen Idec Inc. and Roche AG) and Istodax (romidepsin, Celgene Corp.) Bcl-2 was also the target of another candidate in the company's pipeline, ABT-263 (navitoclax), which showed efficacy but also took a toll on platelets, essential for clotting

Or in the case of Stromedix Inc., which was acquired by Biogen Idec Inc

Biogen Idec Inc.'s move to buy all rights from Elan Corp

The protocol has been expanded to enroll up to 25 additional patients at the 900-mg dose level in the Phase I/II trial evaluating the safety, tolerability and efficacy of ublituximab, the company's third-generation anti-CD20 monoclonal antibody, for patients with rituximab (Rituxan, Biogen Idec Inc. and Roche AG) relapsed or refractory B-cell non-Hodgkin's lymphoma

Examples include Biogen Idec's STX-100, Gilead Science's GS-6624, and FibroGen Inc.'s FG-3019, which target connective tissue growth factor (CTGF